CARISOPRODOL tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

carisoprodol tablet

aphena pharma solutions - tennessee, llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol tablets, usp is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets, usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets, usp is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of carisoprodol during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased

HYDROCORTISONE tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

hydrocortisone tablet

bryant ranch prepack - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - psoriatic arthritis - rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) - ankylosing spondylitis - acute and subacute bursitis - acute nonspecific tenosynovitis - acute gouty arthritis - post-traumatic osteoarthritis - synovitis of osteoarthritis - epicondylitis during an exacerbation or as maintenance therapy in selected cases of: - systemic lupus erythematosus - systemic dermatomyositis (polymyositis) - acut

CARISOPRODOL tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

carisoprodol tablet

bryant ranch prepack - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitation of use carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see dosage and administration (2) ]. carisoprodol tablet is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. risk summary data over many decades of carisoprodol use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. data on meprobamate, the primary metabolite of carisoprodol, also do not show a consistent association between maternal use of meprobamate and an increased risk of major birth defects (see data). in a published animal reproduc

CARISOPRODOL tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

carisoprodol tablet

proficient rx lp - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitation of use carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see dosage and administration (2) ]. carisoprodol tablet is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. risk summary data over many decades of carisoprodol use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. data on meprobamate, the primary metabolite of carisoprodol, also do not show a consistent association between maternal use of meprobamate and an increased risk of major birth defects (see data). in a published animal reproduc

HYDROCORTISONE tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

hydrocortisone tablet

american health packaging - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone tablets are indicated in the following conditions. - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) - congenital adrenal hyperplasia - non suppurative thyroiditis - hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - psoriatic arthritis - rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) - ankylosing spondylitis - acute and subacute bursitis - acute nonspecific tenosynovitis - acute gouty arthritis - post-traumatic osteoarthritis - synovitis of osteoarthritis - epicondylitis during an exacerbation or as maintenance therapy in selected cases of: - systemic lupus erythematosus - systemic dermatomyositis (polymyositis

METOPROLOL TARTRATE- metoprolol tartrate tablet, film coated
METOPROLOL TARTRATE tablet, film coated Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

metoprolol tartrate- metoprolol tartrate tablet, film coated metoprolol tartrate tablet, film coated

bryant ranch prepack - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. angina pectoris metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event. (see dosage and administration,  contraindications, and warnings). hypertension and angina metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see war

METOPROLOL TARTRATE- metoprolol tartrate tablet, film coated Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

metoprolol tartrate- metoprolol tartrate tablet, film coated

aphena pharma solutions - tennessee, llc - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. angina pectoris metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event. (see dosage and administration,  contraindications, and warnings). hypertension and angina metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see war

LEVOCETIRIZINE DIHYDROCHLORIDE tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

levocetirizine dihydrochloride tablet

proficient rx lp - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [ see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function pregnancy category b

LEVOCETIRIZINE DIHYDROCHLORIDE tablet Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

levocetirizine dihydrochloride tablet

bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride tablet is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function. pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, levocetirizine dihydrochloride should be used during pregnancy only if clearly needed. teratogenic effects in rats and rabbits, levocetirizine was not teratogenic at oral doses approximately 320 a

NYSTATIN powder Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

nystatin powder

proficient rx lp - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida albicans  and other susceptible candida species. nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.  nystatin topical powder is contraindicated in patients with a history of hypersensitivity to any of its components.